Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to Sell

Pulse Biosciences (NASDAQ:PLSEGet Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a report issued on Monday.

Pulse Biosciences Price Performance

PLSE traded up $0.14 on Monday, hitting $6.26. The company had a trading volume of 163,369 shares, compared to its average volume of 133,595. Pulse Biosciences has a 52-week low of $1.65 and a 52-week high of $9.69. The stock has a fifty day simple moving average of $4.51 and a 200-day simple moving average of $5.98. The firm has a market capitalization of $344.24 million, a P/E ratio of -6.80 and a beta of 1.25.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, insider Mitchell E. Levinson bought 4,261 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $5.87 per share, with a total value of $25,012.07. Following the completion of the purchase, the insider now owns 73,027 shares of the company’s stock, valued at $428,668.49. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. In other Pulse Biosciences news, insider Mitchell E. Levinson bought 4,261 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $5.87 per share, with a total value of $25,012.07. Following the completion of the purchase, the insider now owns 73,027 shares of the company’s stock, valued at $428,668.49. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert W. Duggan bought 20,241 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were acquired at an average cost of $6.10 per share, with a total value of $123,470.10. Following the purchase, the director now directly owns 36,266,797 shares of the company’s stock, valued at approximately $221,227,461.70. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 29,895 shares of company stock valued at $183,645. Corporate insiders own 64.80% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. TIAA Trust National Association bought a new position in shares of Pulse Biosciences during the third quarter valued at approximately $110,000. California State Teachers Retirement System bought a new stake in shares of Pulse Biosciences during the second quarter valued at approximately $39,000. Osaic Holdings Inc. increased its position in shares of Pulse Biosciences by 4.7% during the second quarter. Osaic Holdings Inc. now owns 58,982 shares of the company’s stock valued at $424,000 after acquiring an additional 2,672 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Pulse Biosciences by 99.9% during the second quarter. Wells Fargo & Company MN now owns 17,397 shares of the company’s stock valued at $125,000 after acquiring an additional 8,694 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Pulse Biosciences during the second quarter valued at approximately $74,000. Institutional investors own 6.62% of the company’s stock.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Featured Articles

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.